
Benedetta Terziroli Beretta-Piccoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2156/publications.pdf Version: 2024-02-01



Benedetta Terziroli

#	Article	IF	CITATIONS
1	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
2	Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clinical Reviews in Allergy and Immunology, 2018, 54, 147-176.	6.5	218
3	Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosisâ€4 score and aspartate aminotransferaseâ€platelet ratio index. Liver International, 2017, 37, 369-376.	3.9	207
4	Antithrombotic treatment with directâ€acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	3.9	178
5	Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. European Journal of Pediatrics, 2000, 159, 594-601.	2.7	158
6	Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World Journal of Gastroenterology, 2017, 23, 6030-6048.	3.3	93
7	The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal of Autoimmunity, 2019, 105, 102328.	6.5	86
8	Current Perspectives on Erythema Multiforme. Clinical Reviews in Allergy and Immunology, 2018, 54, 177-184.	6.5	85
9	Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2017, 53, 337-356.	6.5	81
10	Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?. Journal of Autoimmunity, 2021, 123, 102706.	6.5	77
11	Expert clinical management of autoimmune hepatitis in the real world. Alimentary Pharmacology and Therapeutics, 2017, 45, 723-732.	3.7	66
12	Cutaneous Granulomatosis: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 131-146.	6.5	64
13	Autoimmmune hepatitis. Cellular and Molecular Immunology, 2022, 19, 158-176.	10.5	64
14	Liver injury after SARSâ€CoVâ€2 vaccination: Features of immuneâ€mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology, 2022, 76, 1576-1586.	7.3	58
15	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	4.4	57
16	Autoimmune liver disease serology in acute hepatitis E virus infection. Journal of Autoimmunity, 2018, 94, 1-6.	6.5	39
17	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 936-942.	2.8	37
18	The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. Journal of Autoimmunity, 2018, 95, 144-158.	6.5	35

Benedetta Terziroli

#	Article	IF	CITATIONS
19	Juvenile autoimmune hepatitis: A comprehensive review. Journal of Autoimmunity, 2018, 95, 69-76.	6.5	35
20	Validation of Risk Scoring Systems in Ursodeoxycholic Acid–Treated Patients With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 1101-1108.	0.4	34
21	Serology in autoimmune hepatitis: A clinical-practice approach. European Journal of Internal Medicine, 2018, 48, 35-43.	2.2	33
22	Neurologic complications of acute hepatitis E virus infection. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	32
23	Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clinical Reviews in Allergy and Immunology, 2017, 53, 394-412.	6.5	27
24	Autoimmune sclerosing cholangitis: Evidence and open questions. Journal of Autoimmunity, 2018, 95, 15-25.	6.5	26
25	Nonâ€infectious causes of uveitis in 70 Swiss children. Acta Paediatrica, International Journal of Paediatrics, 2000, 89, 955-958.	1.5	25
26	Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. Liver International, 2018, 38, 619-626.	3.9	25
27	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	3.7	21
28	Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice. Clinical Reviews in Allergy and Immunology, 2022, 63, 124-137.	6.5	20
29	Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. Journal of Autoimmunity, 2021, 116, 102578.	6.5	17
30	Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. Journal of Autoimmunity, 2019, 102, 89-95.	6.5	16
31	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	3.9	15
32	Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. Journal of Viral Hepatitis, 2012, 19, 77-87.	2.0	14
33	Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 299-309.	2.3	14
34	Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clinical Reviews in Allergy and Immunology, 2018, 54, 295-306.	6.5	12
35	ABCB4 variants in adult patients with cholestatic disease are frequent and underdiagnosed. Digestive and Liver Disease, 2021, 53, 329-344.	0.9	11
36	Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. Swiss Medical Weekly, 2018, 148, w14560.	1.6	10

Benedetta Terziroli

#	Article	IF	CITATIONS
37	Atovaquone/proguanilâ€induced autoimmuneâ€like hepatitis. Hepatology Communications, 2017, 1, 293-298.	4.3	8
38	A reasoned approach to the treatment of autoimmune hepatitis. Digestive and Liver Disease, 2021, 53, 1381-1393.	0.9	7
39	A Heterozygous ABCB4, RUNDC3B, and ABCB1 Deletion Associated With Severe Cholestatic Liver Disease in Adulthood. Hepatology, 2019, 70, 1484-1487.	7.3	6
40	Extrarenal Immune-Mediated Disorders Linked with Acute Poststreptococcal Glomerulonephritis: a Systematic Review. Clinical Reviews in Allergy and Immunology, 2019, 57, 294-302.	6.5	5
41	The Pharmacogenetics of Morphine-Induced Analgesia: A Case Report. Journal of Pain and Symptom Management, 2008, 36, e10-e12.	1.2	4
42	Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. PLoS ONE, 2019, 14, e0218706.	2.5	4
43	Infections or Vaccines Associated with Finkelstein-Seidlmayer Vasculitis: Systematic Review. Clinical Reviews in Allergy and Immunology, 2022, , 1.	6.5	3
44	A patient with primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis variant syndrome. Journal of Translational Autoimmunity, 2020, 3, 100033.	4.0	2
45	Is immunosuppression truly associated with worse outcomes in autoimmune hepatitis patients with COVIDâ€19?. Liver International, 2022, 42, 274-276.	3.9	2
46	Antimitochondrial antibodies in patients with autoimmune hepatitis: a large multicenter study. Journal of Hepatology, 2020, 73, S471.	3.7	1
47	Paucisymptomatic hemolytic-uremic syndrome or shigatoxin-associated glomerulonephritic syndrome?. Pediatric Nephrology, 2001, 16, 687-687.	1.7	0
48	Adaptive Immunity and the Clinical Definition of Autoantibodies. , 2020, , 49-68.		0
49	Diagnostic Liver Immunology. , 2020, , 139-150.		0